No Blocking. Red Bolt does not block lawful content, applications, services, or non-harmful devices.
No Blocking. RECIPIENT agrees not to assert any patent or other proprietary right obtained as a result of any use of the Materials that interferes with any manufacture, offer for sale, sale or use of the Materials (or any product made using the Materials or XENOGEN’s Confidential Information) by XENOGEN or any customer or affiliate of XENOGEN. RECIPIENT agrees that such non-assertion of rights shall run with all licenses, sublicenses and assignments of RECIPIENT’s rights in any invention hereunder.
No Blocking. Axiom shall not block lawful content, applications, services, or non-harmful devices.
No Blocking. Common Portions: not place or cause to be placed any article or object in the Common Portions.
No Blocking. Company acknowledges that TiVo, TiVoII and Company may be upgrading the technology provided to Company by TiVoII (or TiVo on its behalf) under this Agreement along similar development paths and, in order to protect TiVoII and TiVo from being blocked from further developing their own technology, Company, on behalf of itself and its Wholly-Owned Subsidiaries, hereby grants TiVo a non-exclusive, non-transferable [*], worldwide (subject to Section 9.3(b)), sublicensable, irrevocable, perpetual: (i) license under any issued patents owned or licensable by Company or its Wholly-Owned Subsidiaries claiming any Upgrades to the Licensed Technology, TiVo Improvements, or TiVo’s Additional Manufacturing Materials, for the life of such patents, to make, have made, use, sell, offer for sale, import or export and otherwise commercially exploit the inventions claimed therein; and (ii) license under Company’s or its Wholly-Owned Subsidiaries’ trade dress rights (or analogous rights in non-U.S. jurisdictions) arising from the use of any visual or audible characteristics generated by any software in the Licensed Technology or TiVo Improvements or any Upgrades of such characteristics.
No Blocking. Licensee agrees not to assert any patent or other proprietary right obtained as a result of any use, while this Agreement is in effect, of the Bioware Materials or LPTA Materials that would block the manufacture, offer for sale, sale or use of the Bioware Materials or LPTA Materials by Xenogen or an Affiliate of Xenogen, or any use of Bioware Materials or LPTA Materials by any customer of Xenogen. Licensee agrees that such non-assertion of rights shall run with all licenses, sublicenses and assignments of Licensee’s rights in any invention covered by this subparagraph (c) that would have such blocking effect. For purposes of clarification, this non-assertion right is not intended in any way to apply to information and materials developed independently of the Bioware Materials or LPTA Materials, including Licensee’s GeneExpress System, any toxicity markers or biomarkers, or to compounds and indications developed by or for Licensee and its Affiliates or resulting from Collaborations.
